Zymeworks Inc.
NASDAQ:ZYMEBiotechnology
-$0.38 today
- Market cap
- $1.80B
- Beta
- 1.14
- P/E (TTM)
- -16.6
- EPS (TTM)
- -$1.37
Volume 0.57M
Average 0.71M
ZYME EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Zymeworks Inc.NASDAQ: ZYME
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA turns positive
Q3 FY2026 EBITDA was $181.65M, compared with -$15.68M a year earlier. Trailing-twelve-month EBITDA was $57.08M.
Context
- EBITDA amounted to 64.8% of revenue in FY2025, down 77.6 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 8 analysts of $150.66M (+319.5%) for the fiscal year ending Dec 2026, a step up from the +36.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $181.65M+519.1% QoQ
- Last fiscal yearDec 2025
- -$68.64M+36.8% YoY
- LTMSep 2026
- $57.08M+205.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1258.3% | -58.8% | -1317.2 pp |
| 1 year | +36.8% | +319.5% | +282.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (68.64M) USD
- Year-over-year change
- +36.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (68.64M) | +36.8% |
| FY2024 | 2024-12-31 | (108.62M) | +10.0% |
| FY2023 | 2023-12-31 | (120.7M) | -184.7% |
| FY2022 | 2022-12-31 | 142.49M | +169.1% |
| FY2021 | 2021-12-31 | (206.09M) | — |
EBITDA vs competitors
How ZYME compares with its peers on the latest reported figures
- ZYME's LTM Sep 2026 EBITDA of $57.08M is the 2nd highest of the 11 companies compared; the peer median is -$84.95M.
- Its year-over-year change of +205.8% is the 3rd highest of 11, against a peer median of -10.6%.
- EBITDA amounts to 21.5% of revenue for ZYME, versus a peer median of 111.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $322.61M | +243.1% | — | 46.0% | |
| LTM Sep 2026 | $57.08M | +205.8% | — | 21.5% | |
| LTM Mar 2026 | $34.88M | +463.6% | — | 48.0% | |
| LTM Mar 2026 | -$50.64M | -7.0% | — | 32.2% | |
| LTM Mar 2026 | -$57.67M | -232.5% | — | 162.2% | |
| LTM Mar 2026 | -$83.2M | +13.7% | — | 105.1% | |
| LTM Mar 2026 | -$86.7M | +32.0% | — | — | |
| LTM Jun 2026 | -$123.6M | -14.3% | — | 117.7% | |
| LTM Mar 2026 | -$158.86M | -1227.0% | — | 1336.8% | |
| LTM Sep 2026 | -$284.54M | -45.7% | — | — | |
| LTM Sep 2026 | -$305.37M | -38.1% | — | 272652.7% | |
| Peer median (excluding ZYME) | -$84.95M | -10.6% | — | 111.4% | |
Competitors are the stored peer set for ZYME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 26.68M | 412.48M | 76.01M | 76.3M | 105.97M |
| Cost of Revenue | 0 | 0 | 142.99M | 0 | 0 |
| Gross Profit | 26.68M | 412.48M | (66.98M) | 76.3M | 105.97M |
| Gross Margin | 100.0% | 100.0% | -88.1% | 100.0% | 100.0% |
| Research & Development | 199.75M | 208.6M | 143.62M | 134.62M | 137M |
| Selling, General & Admin | 42.6M | 73.4M | 70.4M | 61.5M | 61.5M |
| Operating Expenses | 242.31M | 281.95M | 71.08M | 213.41M | 198.5M |
| Depreciation & Amortization | 9.58M | 12M | 17.31M | 11.19M | 11.11M |
| EBITDA | (206.09M) | 142.49M | (120.7M) | (108.62M) | (68.64M) |
| EBITDA Margin | -772.4% | 34.5% | -158.8% | -142.4% | -64.8% |
| Operating Income | (215.63M) | 130.53M | (138.05M) | (137.11M) | (92.54M) |
| Operating Margin | -808.2% | 31.6% | -181.6% | -179.7% | -87.3% |
| Interest Income | 1.97M | 3.6M | 19.71M | 19.94M | 13.35M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 3.27M | 4.71M | 18.81M | 20.5M | 12.78M |
| Income Before Tax | (212.36M) | 135.23M | (119.24M) | (116.61M) | (79.75M) |
| Pre-Tax Margin | -795.9% | 32.8% | -156.9% | -152.8% | -75.3% |
| Income Tax Expense | (516K) | 10.89M | (568K) | 6.08M | 1.38M |
| Net Income | (211.84M) | 124.34M | (118.67M) | (122.7M) | (81.13M) |
| Net Margin | -794.0% | 30.1% | -156.1% | -160.8% | -76.6% |
| EPS (Basic) | (4.06) | 1.91 | (1.72) | (1.62) | (1.08) |
| EPS (Diluted) | (4.61) | 1.90 | (1.72) | (1.62) | (1.08) |
| Weighted Avg Shares | 52.13M | 65.19M | 68.86M | 75.85M | 75.34M |
| Weighted Avg Shares (Diluted) | 52.13M | 65.25M | 68.86M | 75.88M | 75.34M |
Zymeworks Inc.
NASDAQ:ZYME
Intrinsic Alpha fair value
Locked
Current Price
$25.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.